Centene Boosts Full-Year Profit Forecast on Tighter Cost Controls

Health insurer Centene on Tuesday raised its full-year profit and revenue forecasts after reporting second-quarter earnings that significantly surpassed analyst estimates, driven by better-than-expected cost controls. The company's shares rose 2% in pre-market trading following the announcement.

Upgraded Financial Outlook

Centene provided an upgraded financial outlook for the full year, citing a strong performance in the second quarter. The company announced its quarterly adjusted profit was $2.51 per share, well ahead of the $1.09 per share anticipated by analysts, according to LSEG data.

Based on these results, the company updated its guidance:

• Adjusted Profit: Forecast raised to more than $4.80 per share, up from a previous forecast of above $3.40 per share. Analysts had been expecting $3.52.
• Full-Year Revenue: Now projected to be between $193.5 billion and $197.5 billion, an increase from the prior range of $187.5 billion to $191.5 billion.

"Our second-quarter results and improved full-year outlook represent meaningful milestones on our path to restoring profitability and increasing shareholder value," CEO Sarah London said in a statement.

Ad

Improved Cost Management

The stronger-than-expected performance was largely attributed to the company's ability to manage medical expenses. Centene's medical loss ratio (MLR) — the percentage of premiums paid out for medical care — was 89.6% for the second quarter. This was an improvement from 93% in the same period last year and was below analysts' estimates of 91.30%.

According to the company, the lower costs stemmed from improved pricing for its Obamacare health plans and a benefit from risk-adjustment payments. These payments are designed to compensate insurers that cover a higher proportion of members with significant health needs.

Market Context

The positive results come as the U.S. health insurance industry faces pressure from rising medical costs over the past three years. Bernstein analyst Lance Wilkes noted the results were a "solid quarter of progress in margin recovery," adding that the forecast increase will likely shift investor focus to the company's recovery pace in its Medicaid and Marketplace businesses for 2027 and beyond.